Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Cost of Revenue (2016 - 2024)

Historic Cost of Revenue for BioCorRx (BICX) over the last 16 years, with Q1 2024 value amounting to $1667.0.

  • BioCorRx's Cost of Revenue fell 8078.61% to $1667.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $1667.0, marking a year-over-year decrease of 9536.76%. This contributed to the annual value of $1667.0 for FY2024, which is 9536.76% down from last year.
  • Per BioCorRx's latest filing, its Cost of Revenue stood at $1667.0 for Q1 2024, which was down 8078.61% from $13053.0 recorded in Q4 2023.
  • Over the past 5 years, BioCorRx's Cost of Revenue peaked at $28954.0 during Q4 2020, and registered a low of $632.0 during Q1 2021.
  • In the last 5 years, BioCorRx's Cost of Revenue had a median value of $3881.0 in 2023 and averaged $9103.6.
  • Per our database at Business Quant, BioCorRx's Cost of Revenue surged by 71326.24% in 2020 and then tumbled by 9724.43% in 2021.
  • Quarter analysis of 5 years shows BioCorRx's Cost of Revenue stood at $28954.0 in 2020, then crashed by 91.6% to $2431.0 in 2021, then skyrocketed by 256.89% to $8676.0 in 2022, then soared by 50.45% to $13053.0 in 2023, then plummeted by 87.23% to $1667.0 in 2024.
  • Its last three reported values are $1667.0 in Q1 2024, $13053.0 for Q4 2023, and $3881.0 during Q3 2023.